PharmaCyte Biotech Inc. (PMCB) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
23046 AVENIDA DE LA CARLOTA, SUITE 600 LAGUNA HILLS, CA 92653 |
| State of Incorp. | NV |
| Fiscal Year End | April 30 |
| Industry (SIC) | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 1/31/2024 MRQ | 4/30/2023 | 4/30/2022 | 4/30/2021 | 4/30/2020 | 4/30/2019 | 4/30/2018 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 68,040 | 85,401 | 2,202 | 895 | 515 | 1,060 | |||
| Cash and cash equivalents | 68,040 | 85,401 | 2,202 | 895 | 515 | 1,060 | |||
| Other undisclosed current assets | 108 | 94 | 73 | 143 | 138 | 224 | |||
| Total current assets: | 68,148 | 85,495 | 2,275 | 1,038 | 653 | 1,284 | |||
| Noncurrent Assets | |||||||||
| Long-term investments and receivables | 1,572 | 1,572 | 1,572 | 1,572 | 1,572 | 1,572 | |||
| Long-term investments | 1,572 | 1,572 | 1,572 | 1,572 | 1,572 | 1,572 | |||
| Intangible assets, net (including goodwill) | 3,549 | 3,549 | 3,549 | 3,549 | 3,549 | 3,549 | |||
| Intangible assets, net (excluding goodwill) | 3,549 | 3,549 | 3,549 | 3,549 | 3,549 | 3,549 | |||
| Other noncurrent assets | 7 | 7 | 7 | 7 | |||||
| Other undisclosed noncurrent assets | 8 | 8 | |||||||
| Total noncurrent assets: | 5,129 | 5,129 | 5,129 | 5,129 | 5,129 | 5,129 | |||
| TOTAL ASSETS: | 73,277 | 90,624 | 7,404 | 6,167 | 5,782 | 6,413 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 587 | 822 | 725 | 1,002 | 743 | 644 | |||
| Employee-related liabilities | ✕ | ✕ | 118 | ||||||
| Accounts payable | 128 | 205 | 172 | 186 | 122 | 353 | |||
| Accrued liabilities | 458 | 499 | 553 | 817 | 621 | 292 | |||
| Debt | 29 | ||||||||
| Other undisclosed current liabilities | (118) | ||||||||
| Total current liabilities: | 587 | 704 | 725 | 1,031 | 743 | 644 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 46 | ||||||||
| Long-term debt, excluding current maturities | 46 | ||||||||
| Liabilities, other than long-term debt | |||||||||
| Derivative instruments and hedges, liabilities | |||||||||
| Other undisclosed noncurrent liabilities | |||||||||
| Total noncurrent liabilities: | 46 | ||||||||
| Total liabilities: | 587 | 704 | 725 | 1,078 | 743 | 644 | |||
| Equity | |||||||||
| Equity, attributable to parent | 72,690 | 89,920 | 6,679 | 5,089 | 5,040 | 5,769 | |||
| Common stock | 2 | 2 | 0 | 164 | 119 | 101 | |||
| Treasury stock, value | (13,561) | ||||||||
| Additional paid in capital | 202,231 | 201,582 | 114,109 | 108,805 | 104,966 | 101,636 | |||
| Accumulated other comprehensive loss | (23) | (16) | (20) | (22) | (14) | (5) | |||
| Accumulated deficit | (115,959) | (111,649) | (107,409) | (103,858) | (100,031) | (95,964) | |||
| Other undisclosed equity | |||||||||
| Total equity: | 72,690 | 89,920 | 6,679 | 5,089 | 5,040 | 5,769 | |||
| TOTAL LIABILITIES AND EQUITY: | 73,277 | 90,624 | 7,404 | 6,167 | 5,782 | 6,413 | |||
Income Statement (P&L) ($ in thousands)
| 1/31/2024 TTM | 4/30/2023 | 4/30/2022 | 4/30/2021 | 4/30/2020 | 4/30/2019 | 4/30/2018 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 33 | 153 | ||||||
| Other income | (1) | (0) | 33 | 153 | ||||
| Gross profit: | 33 | 153 | ||||||
| Operating expenses | (6,455) | (4,392) | (3,623) | (3,826) | (4,101) | (6,981) | ||
| Other undisclosed operating income (loss) | 1 | 0 | (33) | (153) | ||||
| Operating loss: | (6,455) | (4,392) | (3,623) | (3,826) | (4,101) | (6,981) | ||
| Nonoperating income (expense) | 2,140 | 153 | 72 | (0) | 33 | 153 | ||
| Other nonoperating income (expense) | 202 | (4) | 72 | (0) | 33 | 153 | ||
| Interest and debt expense | (1) | (3) | (0) | |||||
| Loss from continuing operations: | (4,316) | (4,240) | (3,554) | (3,827) | (4,067) | (6,829) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | (4,240) | (3,554) | (3,827) | (4,067) | (6,829) | |
| Net loss: | (4,316) | (4,240) | (3,554) | (3,827) | (4,067) | (6,829) | ||
| Other undisclosed net income attributable to parent | 1 | 3 | 0 | |||||
| Net loss attributable to parent: | (4,316) | (4,239) | (3,551) | (3,827) | (4,067) | (6,829) | ||
| Other undisclosed net loss available to common stockholders, basic | ||||||||
| Net loss available to common stockholders, diluted: | (4,316) | (4,239) | (3,551) | (3,827) | (4,067) | (6,829) | ||
Comprehensive Income ($ in thousands)
| 1/31/2024 TTM | 4/30/2023 | 4/30/2022 | 4/30/2021 | 4/30/2020 | 4/30/2019 | 4/30/2018 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (4,316) | (4,240) | (3,554) | (3,827) | (4,067) | (6,829) | ||
| Other comprehensive income (loss) | (7) | 5 | 1 | (8) | (9) | (6) | ||
| Comprehensive loss: | (4,323) | (4,235) | (3,553) | (3,835) | (4,076) | (6,835) | ||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | 1 | 3 | 0 | |||||
| Comprehensive loss, net of tax, attributable to parent: | (4,323) | (4,235) | (3,550) | (3,835) | (4,076) | (6,835) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.